Nanjing Iaso Biotechnology Co., Ltd.

This study tests a new treatment called Equecabtagene autoleucel for people with multiple myeloma that has come back or stopped responding to standard therapies. The treatment uses a patient's own immune cells, modified to target and attack cancer cells. The goal is to control th…